VIVUS Inc. (VVUS)
Symbol Info
Listed Symbol VVUS
Name VIVUS Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $65,062,000
Latest Fiscal EPS $-3.47
Price Info
21 Day Moving Average $3.3564
21 Day EMA $3.382880
50 Day Moving Average $3.4291
50 Day EMA $3.474990
200 Day EMA $4.022150
200 Day Moving Average 3.749700
52 Week High $6.48
52 Week Low $2.15
52 Week Change $-49.448800
Alpha -0.030714
Beta 1.8510
Standard Deviation 0.255888
R2 0.062991
Periods 60
Share Information
10 Day Average Volume 20,003
20 Day Average Volume 20,522
30 Day Average Volume 19,742
50 Day Average Volume 23,475
Outstanding Shares 10,642,713
Float Shares 8,173,942
Percent Float 76.80%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 59
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 119,634
Institute Holdings Percent 17.700000
Institute Sold Previous 3 Months 222,029
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 23.20%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,468,771
Price Change
7 Day Price Change $-0.1800001
7 Day Percent Change -5.31%
21 Day Price Change $-0.1700001
21 Day Percent Change -5.03%
30 Day Price Change $-0.1800001
30 Day Percent Change -5.31%
Month To Date Price Change $-0.13
Month To Date Percent -3.89%
90 Day Price Change $-0.75
90 Day Percent Change -18.94%
Quarter To Date $-0.61
Quarter To Date Percent -15.97%
180 Day Price Change $-1.89
180 Day Percent Change -37.06%
200 Day Price Change $-1.29
200 Day Percent Change -28.67%
Year To Date $0.980000
Year To Date Percent 43.95%
Profile
Description VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and Stendra/Spedra, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. The company operates through the single segment of business being Development and commercialization of novel therapeutic products.
Details
Issue Type CS
Market Cap $34,163,109
Sec Type EQS
Auditor OUM & Co. LLP
Total Shares Outstanding 10,642,713
CEO John Amos
Employees 57
Last Audit UQ
Classification
CIK 0000881524
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 900 East Hamilton Avenue
Suite 550
Campbell, CA 95008
Website http://www.vivus.com
Facisimile +1 855 298-9012
Telephone +1 650 934-5200
Email oki@vivus.com
Key Ratios
Profitability
EBIT Margin -4.8
EBITDA Margin 15.4
Pre-Tax Profit Margin -51
Profit Margin Cont -37.95
Gross Margin 76.10
Profit Margin TOT -37.95
Income Statements
Revenue $72,738,000
Revenue Per Share $6.8345
Revenue 3 Years $-9.51
Revenue 5 Years $-11.75
Valuation Measures
PE Ratio -
Enterprise Value $236,239,932
Price To Sales 0.469673
Price To Free Cash -1.6
PE High Last 5 Years -
Price To Book 127.2
Price To Cash Flow 1.6
PE Low Last 5 Years -
Price To Tangible Book -0.2
Financial Strength
Total Debt To Equity -
Int Coverage -0.1
Current Ratio 0.7
Leverage Ratio -6.7
Quick Ratio 0.5
Long Term Debt To Capital -
Assets
Receivables Turnover 1.9
Invoice Turnover 0.70
Assets Turnover 0.10
Management Effectiveness
Return Assets -9.36
Return On Equity 68.71
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
VVUS
VIVUS
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.